Contact
QR code for the current URL

Story Box-ID: 523128

Rottendorf Pharma GmbH Ostenfelder Str. 51-61 59320 Ennigerloh, Germany http://www.rottendorf.de
Contact Ms Anna Beck +49 2524 268648
Company logo of Rottendorf Pharma GmbH
Rottendorf Pharma GmbH

Rottendorf Pharma GmbH Participating in Project Dedicated to Tumor Therapy Research

(PresseBox) (Ennigerloh, )
Together with other associate partners Rottendorf Pharma GmbH is currently participating in a research project dedicated to photodynamic tumor therapy. A project embedded in the so called "Medi-WING" promotion program, supported by the German Ministry of Education and Research (BMBF).

Ms. Stefanie Krenzlin, representative of Rottendorf Pharma, together with six public and industrial partners investigates suitable active substances for tumor therapy. Primary objective is to enhance scientific knowledge and develop innovative dosage forms. Additionally the project aims at strengthening the German pharmaceutical industry within the field of nanotechnology and enhancing its competitiveness.

In the past suitable active substances for tumor treatment have already been explored and permitted to the market. Recently, photostabilizers were classified as an innovative and highly promising category of substances. The distinctive feature of this drug class lies in its local effectiveness. The ingested photostabilizers are specifically activated through laser light and destroy cancer cells. As a consequence from this method further damage of healthy cells can be minimized.

In general the patient's wellbeing is in the focus of every tumor therapy. Within the framework of the research project the common injection of photostabilizers associated with pain shall ideally be replaced by an easy to administer oral solid dosage. Furthermore it allows to reduce the duration of inpatient treatment.

With the help of substances from the class of photosensitizing the project group faces the challenge to develop a solid oral formulation. The overall aim is to decrease undesired side effects and at the same time ensure good bio-availability. Due to Rottendorf's experience with industrial production and in order to ensure the formulation to become authorized for the market - Rottendorf Pharma GmbH will once passing the development phase - continue to be responsible for the upscaling. Rottendorf's exceptionally comprehensive expertise in the development of pharmaceutically solid dosage forms, as well as the new GMP- and FDA approved "Development and Upscaling Center," offer optimal conditions for this project.
The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2024, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.